Постэксцизионная вакцинация против вируса папилломы человека как метод вторичной профилактики цервикальной интраэпителиальной неоплазии 2+

1. Athanasiou A., Veroniki A.A., Efthimiou O., Kalliala I., Naci H., Bowden S. et al. Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis. Lancet Oncol. 2022; 23(8): 1097-108. https://dx.doi.org/10.1016/S1470-2045(22)00334-5.
2. Kalliala I., Athanasiou A., Veroniki A.A., Salanti G., Efthimiou O., Raftis N. et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann. Oncol. 2020; 31(2): 213-27. https://dx.doi.org/10.1016/j.annonc.2019.11.004.
3. Arbyn M., Redman C.W.E., Verdoodt F., Kyrgiou M., Tzafetas M., Ghaem-Maghami S. et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017; 18(12): 1665-79. https://dx.doi.org/10.1016/S1470-2045(17)30700-3.
4. Tanaka Y., Ueda Y., Kakuda M., Kubota S., Matsuzaki S, Iwamiya T. et al. Predictors for recurrent/persistent high-grade intraepithelial lesions and cervical stenosis after therapeutic conization: a retrospective analysis of 522 cases. Int. J. Clin. Oncol. 2017; 22(5): 921-6. https://dx.doi.org/10.1007/s10147-017-1124-z.
5. Fan A., Wang C., Han C., Wang Y., Xue F., Zhang L. Factors affecting residual/recurrent cervical intraepithelial neoplasia after cervical conization with negative margins. J. Med. Virol. 2018; 90(9): 1541-8. https://dx.doi.org/10.1002/jmv.25208.
6. Bittencourt D.D., Zanine R.M., Sebastião A.P.M., Ribas C.M. Risk factors for persistence or recurrence of high-grade cervical squamous intraepithelial lesions. Rev. Col. Bras. Cir. 2023; 50: e20233537. https://dx.doi.org/10.1590/0100-6991e-20233537-en.
7. Ikeda M., Mikami M., Yasaka M., Enomoto T., Kobayashi Y., Nagase S. et al. Association of menopause, aging and treatment procedures with positive margins after therapeutic cervical conization for CIN 3: a retrospective study of 8,856 patients by the Japan Society of Obstetrics and Gynecology. J. Gynecol. Oncol. 2021; 32(5): e68. https://dx.doi.org/10.3802/jgo.2021.32.e68.
8. Murakami I., Ohno A., Ikeda M., Yamashita H., Mikami M., Kobayashi Y. et al. Analysis of pathological and clinical characteristics of cervical conization according to age group in Japan. Heliyon. 2020; 6(10): e05193. https://dx.doi.org/10.1016/j.heliyon.2020.e05193.
9. Sand F.L., Frederiksen K., Kjaer S.K. Risk of recurrent disease following conization of cervical intraepithelial neoplasia grade 3 according to post-conization HPV status and surgical margins. Gynecol. Oncol. 2022; 165(3): 472-7. https://dx.doi.org/10.1016/j.ygyno.2022.03.015.
10. Giannini A., Di Donato V., Sopracordevole F., Ciavattini A., Ghelardi A., Vizza E. et al. Outcomes of high-grade cervical dysplasia with positive margins and HPV persistence after cervical conization. Vaccines (Basel). 2023; 11(3): 698. https://dx.doi.org/10.3390/vaccines11030698.
11. Papoutsis D., Underwood M., Parry-Smith W., Tzavara C. Endocervical crypt involvement by high-grade cervical intraepithelial neoplasia and its association with high-grade histopathological recurrence after cervical excision in women with negative excision margins: a systematic review and meta-analysis. Arch. Gynecol. Obstet. 2024; 309(3): 939-48. https://dx.doi.org/10.1007/s00404-023-07242-y.
12. Byun J.M., Jeong D.H., Kim Y.N., Jung E.J., Lee K.B., Sung M.S. et al. Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia. Medicine (Baltimore). 2018; 97(51): e13606. https://dx.doi.org/10.1097/MD.0000000000013606.
13. Zhang Y., Ni Z., Wei T., Liu Q. Persistent HPV infection after conization of cervical intraepithelial neoplasia - a systematic review and meta-analysis. BMC Womens Health. 2023; 23(1): 216. https://dx.doi.org/10.1186/s12905-023-02360-w.
14. Garutti P., Borghi C., Bedoni C., Bonaccorsi G., Greco P., Tognon M. et al. HPV-based strategy in follow-up of patients treated for high-grade cervical intra-epithelial neoplasia: 5-year results in a public health surveillance setting. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 210: 236-41. https://dx.doi.org/10.1016/j.ejogrb.2016.12.018.
15. Swedish K.A., Factor S.H., Goldstone S.E. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin. Infect. Dis. 2012; 54(7): 891-8. https://dx.doi.org/10.1093/cid/cir1036.
16. Ghelardi A., Marrai R., Bogani G., Sopracordevole F., Bay P., Tonetti A. et al. Surgical treatment of vulvar HSIL: adjuvant HPV vaccine reduces recurrent disease. Vaccines (Basel). 2021; 9(2): 83. https://dx.doi.org/10.3390/vaccines9020083.
17. Joura E.A., Garland S.M., Paavonen J., Ferris D.G., Perez G., Ault K.A. et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012; 344: e1401. https://dx.doi.org/10.1136/bmj.e1401.
18. Chen M., Li C., Cui Q., Zhou C., Chen P., Yao S. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: a prospective observational study in China. Eur. J. Obstet. Gynecol. Reprod. Biol. 2023; 286: 10-5. https://dx.doi.org/10.1016/j.ejogrb.2023.04.014.
19. Kechagias K.S., Kalliala I., Bowden S.J., Athanasiou A., Paraskevaidi M., Paraskevaidis E. et al. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis. BMJ. 2022; 378: e070135. https://dx.doi.org/10.1136/bmj-2022-070135.
20. Eriksen D.O., Jensen P.T., Schroll J.B., Hammer A. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: a systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2022; 101(6): 597-607. https://dx.doi.org/10.1111/aogs.14359.
21. Petráš M., Dvořák V., Lomozová D., Máčalík R., Neradová S., Dlouhý P. et al. Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression. Sex. Transm. Infect. 2023; 99(8): 561-70. https://dx.doi.org/10.1136/sextrans-2023-055793.
22. Jentschke M., Kampers J., Becker J., Sibbertsen P., Hillemanns P. Prophylactic HPV vaccination after conization: a systematic review and meta-analysis. Vaccine. 2020; 38(41): 6402-9. https://dx.doi.org/10.1016/j.vaccine.2020.07.055.
23. Casajuana-Pérez A., Ramírez-Mena M., Ruipérez-Pacheco E., Gil-Prados I., García-Santos J., Bellón-Del Amo M. et al. Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL/CIN 2-3: the VENUS study. Vaccines (Basel). 2022; 10(2): 288. https://dx.doi.org/10.3390/vaccines10020288.
24. Di Donato V., Caruso G., Petrillo M., Kontopantelis E., Palaia I., Perniola G. et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis. Vaccines (Basel). 2021; 9(5): 410. https://dx.doi.org/10.3390/vaccines9050410.
25. Lichter K., Krause D., Xu J., Tsai S.H.L., Hage C., Weston E. et al. Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis. Obstet. Gynecol. 2020; 135(5): 1070-83. https://dx.doi.org/10.1097/AOG.0000000000003833.
26. Chaiken S.R., Bruegl A.S., Caughey A.B., Emerson J., Munro E.G. Adjuvant human papillomavirus vaccination after excisional procedure for cervical intraepithelial neoplasia: a cost-effectiveness analysis. Obstet. Gynecol. 2023; 141(4): 756-63. https://dx.doi.org/10.1097/AOG.0000000000005106.
27. Reuschenbach M., Doorbar J., Del Pino M., Joura E.A., Walker C., Drury R. et al. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer. Vaccine. 2023; 41(42): 6194-205. https://dx.doi.org/10.1016/j.vaccine.2023.08.047.
28. Wei F., Su Y., Cui X., Yu X., Li Y., Song Q. et al. Sequential acquisition of human papillomavirus infection at genital and anal sites, Liuzhou, China. Emerg. Infect. Dis. 2020; 26(10): 2387-93. https://dx.doi.org/10.3201/eid2610.191646.
29. Sand F.L., Kjaer S.K., Frederiksen K., Dehlendorff С. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int. J. Cancer. 2020; 147(3): 641-7. https://dx.doi.org/10.1002/ijc.32752.
30. Henere C., Torné A., Llupià A., Aldea M., Martí C., Glickman A. et al. HPV vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: insights into unsolved questions. Vaccines (Basel). 2022; 10(6): 887. https://dx.doi.org/10.3390/vaccines10060887.
31. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J. et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 2015; 372(8): 711-23. https://dx.doi.org/10.1056/NEJMoa1405044.
32. Dvořák V., Petráš M., Dvořák V., Lomozová D., Dlouhý P., Králová Lesná I. et al. Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: retrospective cohort study. Hum. Vaccin. Immunother. 2024; 20(1): 2343552. https://dx.doi.org/10.1080/21645515.2024.2343552.

Поступила 27.08.2024

Принята в печать 29.11.2024